The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model
Open accessAbstract
Importance: The age-based or "one-size-fits-all" breast screening approach does not take into account the individual variation in risk. Mammography screening reduces death from breast cancer at the cost of overdiagnosis. Identifying risk-stratified screening strategies with a more favorable ratio of overdiagnoses to breast cancer deaths prevented would improve the quality of life of women and save resources. Objective: To assess the benefit-to-harm ratio and the cost-effectiveness of risk-stratified breast screening programs compared with a standard age-based screening program and no screening. Design, Setting, and Population: A life-table model was created of a hypothetical cohort of 364 500 women in the United Kingdom, aged 50 years, with follow-up to age 85 years, using (1) findings of the Independent UK Panel on Breast Cancer Screening and (2) risk distribution based on polygenic risk profile. The analysis was undertaken from the National Health Service perspective. Interventions: The modeled interventions were (1) no screening, (2) age-based screening (mammography screening every 3 years from age 50 to 69 years), and (3) risk-stratified screening (a proportion of women aged 50 years with a risk score greater than a threshold risk were offered screening every 3 years until age 69 years) considering each percentile of the risk distribution. All analyses took place between July 2016 and September 2017. Main Outcomes and Measures: Overdiagnoses, breast cancer deaths averted, quality-adjusted life-years (QALYs) gained, costs in British pounds, and net monetary benefit (NMB). Probabilistic sensitivity analyses were used to assess uncertainty around parameter estimates. Future costs and benefits were discounted at 3.5% per year. Results: The risk-stratified analysis of this life-table model included a hypothetical cohort of 364 500 women followed up from age 50 to 85 years. As the risk threshold was lowered, the incremental cost of the program increased linearly, compared with no screening, with no additional QALYs gained below 35th percentile risk threshold. Of the 3 screening scenarios, the risk-stratified scenario with risk threshold at the 70th percentile had the highest NMB, at a willingness to pay of £20 000 (US $26 800) per QALY gained, with a 72% probability of being cost-effective. Compared with age-based screening, risk-stratified screening at the 32nd percentile vs 70th percentile risk threshold would cost £20 066 (US $26 888) vs £537 985 (US $720 900) less, would have 26.7% vs 71.4% fewer overdiagnoses, and would avert 2.9% vs 9.6% fewer breast cancer deaths, respectively. Conclusions and Relevance: Not offering breast cancer screening to women at lower risk could improve the cost-effectiveness of the screening program, reduce overdiagnosis, and maintain the benefits of screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The benefits and harms of breast cancer screening: an independent review
Marmot, M. G. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61611-0 · Cited by 1,495
Association analysis identifies 65 new breast cancer risk loci
Michailidou, K., Lindström, S., Dennis, J., Beesley, J., Hui, S., Kar, S., Lemaçon, A., Soucy, P., Glubb, D. M., Rostamianfar, A., et al. (2017) · Nature · doi:10.1038/nature24284 · Cited by 1,380
Higgins (2002) · doi:10.1002/(issn)1097-0258 · Cited by 1,248
Polygenic susceptibility to breast cancer and implications for prevention
Pharoah, P. D. P., Antoniou, A. C., Bobrow, M., Zimmern, R. L., Easton, D. F., & Ponder, B. A. J. (2002) · Nature Genetics · doi:10.1038/ng853 · Cited by 898
Self-citationMaas, P., Barrdahl, M., Joshi, A. D., Auer, P. L., Gaudet, M. M., Milne, R. L., Schumacher, F. R., Anderson, W. F., Check, D., Chattopadhyay, S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1025 · Cited by 373
Schousboe, J. T., Kerlikowske, K. M., Loh, A., & Cummings, S. R. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-1-201107050-00003 · Cited by 317
Duffy, S. W., Chen, H., Tabár, L. K., & Day, N. E. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141404 · Cited by 208
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening
Pashayan, N., Duffy, S. W., Chowdhury, S., Dent, T., Burton, H., Neal, D. E., Easton, D. F., Eeles, R. A., & Pharoah, P. D. P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.118 · Cited by 160
Self-citationEvans, D. G., Astley, S., Stavrinos, P., Harkness, E. F., Donnelly, L. S., Dawe, S., Jacob, I., Harvie, M., Cuzick, J. M., Brentnall, A. R., et al. (2016) · Programme Grants for Applied Research · doi:10.3310/pgfar04110 · Cited by 153
Cost-Effectiveness and Harm-Benefit Analyses of Risk-Based Screening Strategies for Breast Cancer
Vilaprinyó, E., Forné, C., Carles-Lavila, M., Sala, M., Pla, R., Castells, X., Domingo, L., Rué, M., & the Interval Cancer (INCA) Study Group (2014) · PLoS ONE · doi:10.1371/journal.pone.0086858 · Cited by 142
Research works printed but not linked: 1
- Dent, 2014, Stratified Screening for Cancer: Recommendations and Analysis From the COGS Project
Cited by
Sorted by citations
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Lee, A., Mavaddat, N., Hurson, A. N., Cunningham, A. P., Carver, T. J., Hartley, S., de Villiers, C. B., Izquierdo, Á., Simard, J., Schmidt, M. K., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-018-0406-9 · Cited by 725
Self-citationTowards clinical utility of polygenic risk scores
Lambert, S. A., Abraham, G., & Inouye, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz187 · Cited by 586
[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures
Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., & Belay, A. (2022) · BioMed Research International · doi:10.1155/2022/9605439 · Cited by 604
RetractedThe future of early cancer detection
Fitzgerald, R. C., Antoniou, A. C., Fruk, L., & Rosenfeld, N. (2022) · Nature Medicine · doi:10.1038/s41591-022-01746-x · Cited by 486
Personalized early detection and prevention of breast cancer: ENVISION consensus statement
Pashayan, N., Antoniou, A. C., Ivanuš, U., Esserman, L. J., Easton, D. F., French, D., Sroczynski, G., Hall, P. N., Cuzick, J. M., Evans, D. G., et al. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0388-9 · Cited by 455
Self-citationO’Sullivan, J. W., Raghavan, S., Márquez‐Luna, C., Luzum, J. A., Damrauer, S. M., Ashley, E. A., O’Donnell, C. J., Willer, C. J., & Natarajan, P. (2022) · Circulation · doi:10.1161/cir.0000000000001077 · Cited by 443
Circulating cell-free DNA for cancer early detection
Gao, Q., Zeng, Q., Wang, Z., Li, C., Xu, Y., Cui, P., Xin, Z., Lu, H., Wang, G., Cai, S., et al. (2022) · The Innovation · doi:10.1016/j.xinn.2022.100259 · Cited by 161
Yanes, T., Young, M., Meiser, B., & James, P. A. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01260-3 · Cited by 152
Lim, Y. X., Lim, Z. L., Ho, P. J., & Li, J. (2022) · Cancers · doi:10.3390/cancers14174218 · Cited by 161
Ho, W.-K., Tan, M., Mavaddat, N., Tai, M.-C., Mariapun, S., Li, J., Ho, P. J., Dennis, J., Tyrer, J. P., Bolla, M. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17680-w · Cited by 125
Self-citationThe current status of risk-stratified breast screening
Clift, A. K., Dodwell, D. J., Lord, S., Petrou, S., Brady, M., Collins, P. G. S., & Hippisley‐Cox, J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01550-3 · Cited by 142
Brooks, J. D., Nabi, H., Andrulis, I. L., Antoniou, A. C., Chiquette, J., Després, P., Devilee, P., Dorval, M., Droit, A., Easton, D. F., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060511 · Cited by 120
Self-citationFamily health history: underused for actionable risk assessment
Ginsburg, G. S., Wu, R. R., & Orlando, L. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31275-9 · Cited by 105
Choudhury, P. P., Hurson, A. N., Brook, M. N., Zhang, Y., Ahearn, T. U., Orr, N., Coulson, P., Schoemaker, M. J., Jones, M. E., Gail, M. H., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz113 · Cited by 103
Incorporating carbon into health care: adding carbon emissions to health technology assessments
McAlister, S., Morton, R. L., & Barratt, A. L. (2022) · The Lancet Planetary Health · doi:10.1016/s2542-5196(22)00258-3 · Cited by 106
Precision public health in the era of genomics and big data
Roberts, M. C., Holt, K. E., Fiol, G. D., Baccarelli, A., & Allen, C. G. (2024) · Nature Medicine · doi:10.1038/s41591-024-03098-0 · Cited by 99
Lakeman, I. M. M., Rodríguez‐Girondo, M., Lee, A., Ruiter, R., Stricker, B. H. C., Wijnant, S. R. A., Kavousi, M., Antoniou, A. C., Schmidt, M. K., Uitterlinden, A. G., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0884-4 · Cited by 82
Risk-based breast cancer screening strategies in women
Harkness, E. F., Astley, S., & Evans, D. G. (2019) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2019.11.005 · Cited by 83
Callender, T., Emberton, M., Stephen Morris, A., Eeles, R. A., Kote‐Jarai, Z., Pharoah, P. D. P., & Pashayan, N. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002998 · Cited by 79
Self-citationThe emerging field of polygenic risk scores and perspective for use in clinical care
Yanes, T., McInerney-Leo, A. M., Law, M. H., & Cummings, S. A. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa136 · Cited by 75
Hurson, A. N., Choudhury, P. P., Gao, C., Hüsing, A., Eriksson, M., Shi, M., Scott, C., Carter, B. D., Martin, K., Harkness, E., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab036 · Cited by 75
Psychosocial and behavioral outcomes of genomic testing in cancer: a systematic review
Yanes, T., Willis, A. M., Meiser, B., Tucker, K., & Best, M. C. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0257-5 · Cited by 73
Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History
van den Broek, J. J., Schechter, C. B., van Ravesteyn, N. T., Janssens, A. C. J. W., Wolfson, M. C., Trentham‐Dietz, A., Simard, J., Easton, D. F., Mandelblatt, J. S., Kraft, P., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa127 · Cited by 71
Shang, C., & Xu, D. (2022) · ONCOLOGIE · doi:10.32604/oncologie.2022.027640 · Cited by 77
Naber, S. K., Kundu, S., Kuntz, K. M., Dotson, W. D., Williams, M. S., Zauber, A. G., Calonge, N., Zallen, D. T., Ganiats, T. G., Webber, E. M., et al. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz086 · Cited by 64
Briggs, S., Law, P., East, J. E., Wordsworth, S., Dunlop, M. G., Houlston, R. S., Hippisley‐Cox, J., & Tomlinson, I. P. M. (2022) · BMJ · doi:10.1136/bmj-2022-071707 · Cited by 72
Roberts, M. C., Fohner, A. E., Landry, L. G., Olstad, D. L., Smit, A. K., Turbitt, E., & Allen, C. G. (2021) · Genome Medicine · doi:10.1186/s13073-021-00911-0 · Cited by 67
Prediction models for depression risk among older adults: systematic review and critical appraisal
Tan, J., Ma, C., Zhu, C., Wang, Y., Zou, X., Li, H., Li, J., He, Y., & Wu, C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101803 · Cited by 64
Clinical use of polygenic risk scores: current status, barriers and future directions
Kullo, I. J. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-025-00900-8 · Cited by 73
Jayasekera, J. C., & Mandelblatt, J. S. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01525 · Cited by 62
Callender, T., Emberton, M., Stephen Morris, A., Pharoah, P. D. P., & Pashayan, N. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.37657 · Cited by 61
Self-citationGhanouni, A., Sanderson, S. C., Pashayan, N., Renzi, C., von Wagner, C., & Waller, J. (2019) · Journal of Medical Screening · doi:10.1177/0969141319883662 · Cited by 60
Self-citationMbuya-Bienge, C., Pashayan, N., Brooks, J. D., Dorval, M., Chiquette, J., Eloy, L., Turgeon, A., Lambert-Côté, L., Paquette, J., Lévesque, E., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020095 · Cited by 58
Self-citationJanda, M., Cust, A. E., Neale, R. Ε., Aitken, J. F., Baade, P. D., Green, A. C., Khosrotehrani, K., Mar, V., Soyer, H. P., & Whiteman, D. C. (2020) · Australian and New Zealand Journal of Public Health · doi:10.1111/1753-6405.12972 · Cited by 67
Mesa‐Eguiagaray, I., Wild, S. H., Rosenberg, P. S., Bird, S. M., Brewster, D., Hall, P. S., Cameron, D., Morrison, D. S., & Figueroa, J. D. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0938-z · Cited by 54
Financial Burden of Hepatocellular Carcinoma Screening in Patients With Cirrhosis
Narasimman, M., Hernáez, R., Cerda, V., Lee, M., Yekkaluri, S., Khan, A., Sood, A., Gurley, T., Quirk, L., Liu, Y., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.07.018 · Cited by 54
Risk-Based vs Annual Breast Cancer Screening
Esserman, L. J., Fiscalini, A. S., Naeim, A., Veer, L. J. V., Kaster, A., Scheuner, M. T., LaCroix, A. Z., Borowsky, A. D., Anton‐Culver, H., Olopade, O. I., et al. (2025) · JAMA · doi:10.1001/jama.2025.24784 · Cited by 54
Personalized breast cancer screening strategies: A systematic review and quality assessment
Román, M., Sala, M., Domingo, L., Posso, M., Louro, J., & Castells, X. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226352 · Cited by 54
Hindmarch, S., Hawkes, R. E., Howell, S. J., Gorman, L. S., & French, D. (2021) · Cancers · doi:10.3390/cancers13164150 · Cited by 54
Robbins, H. A., Ferreiro-Iglesias, A., Waterboer, T., Brenner, N., Nygård, M., Bender, N., Schroeder, L., Hildesheim, A., Pawlita, M., DʼSouza, G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01785 · Cited by 53
Rainey, L., van der Waal, D., & Broeders, M. J. M. (2020) · BMC Cancer · doi:10.1186/s12885-020-07464-2 · Cited by 52
Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer
Mukama, T., Kharazmi, E., Xu, X., Sundquist, K., Sundquist, J., Brenner, H., & Fallah, M. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3876 · Cited by 49
Barriers in Latin America for the management of locally advanced breast cancer
Pinto, J. A., Pinillos, L., Villarreal-Garza, C. M., Morante, Z., Villarán, M., Mejía, G., Caglevic, C., Aguilar, A., Fajardo, W., Torres, F. A. U., et al. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.897 · Cited by 48
Towards a cancer mission in Horizon Europe: recommendations
Berns, A. J. M., Ringborg, U. K., Celis, J. E., Heitor, M. V., Aaronson, N. K., Abou‐Zeid, N., Adami, H., Apostolidis, K., Baumann, M. A., Bardelli, A., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12763 · Cited by 47
McWilliams, L., Woof, V. G., Donnelly, L. S., Howell, A., Evans, D. G., & French, D. (2020) · BMC Cancer · doi:10.1186/s12885-020-07158-9 · Cited by 43
Saunders, C. L., Kilian, B., Thompson, D. J., McGeoch, L. J., Griffin, S. J., Antoniou, A. C., Emery, J. D., Walter, F. M., Dennis, J., Yang, X., et al. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-19-0521 · Cited by 42
Benafif, S., Raghallaigh, H. N., McGrowder, E. H., Saunders, E. J., Brook, M. N., Saya, S., Rageevakumar, R., Wakerell, S., James, D., Chamberlain, A., et al. (2021) · British Journal of Urology · doi:10.1111/bju.15535 · Cited by 42
Can polygenic risk scores contribute to cost-effective cancer screening? A systematic review
Dixon, P., Keeney, E., Taylor, J. C., Wordsworth, S., & Martin, R. M. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2022.04.020 · Cited by 41
Cenin, D. R., Naber, S. K., de Weerdt, A. C., Jenkins, M. A., Preen, D. B., Ee, H. C., O'Leary, P. C., & Lansdorp‐Vogelaar, I. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1123 · Cited by 40
Coignard, J., Lush, M. J., Beesley, J., O’Mara, T. A., Dennis, J., Tyrer, J. P., Barnes, D. R., McGuffog, L., Leslie, G., Bolla, M. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20496-3 · Cited by 44
Christiansen, S. R., Autier, P., & Støvring, H. (2022) · European Journal of Public Health · doi:10.1093/eurpub/ckac047 · Cited by 39
de Villiers, C. B., Kroese, M., & Moorthie, S. A. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106763 · Cited by 41
Mital, S., & Nguyen, H. V. (2022) · BMC Cancer · doi:10.1186/s12885-022-09613-1 · Cited by 38
Using Big Data and Predictive Analytics to Determine Patient Risk in Oncology
Parikh, R. B., Gdowski, A., Patt, D. A., Hertler, A. A., Mermel, C. H., & Bekelman, J. E. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238891 · Cited by 40
Population-based Genetic Testing for Precision Prevention
Evans, O., & Manchanda, R. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0002 · Cited by 38
Hutsebaut, J., Clarke, S. L., & Chanen, A. M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130417 · Cited by 36
Rainey, L., van der Waal, D., Jervaeus, A., Donnelly, L. S., Evans, D. G., Hammarström, M., Hall, P. N., Wengström, Y., & Broeders, M. J. M. (2020) · BMC Cancer · doi:10.1186/s12885-020-06745-0 · Cited by 36
Dunlop, K. L. A., Rankin, N. M., Smit, A. K., Salgado, Z., Newson, A. J., Keogh, L. A., & Cust, A. E. (2021) · Health Expectations · doi:10.1111/hex.13267 · Cited by 35
Mühlberger, N., Sroczynski, G., Gogollari, A., Jahn, B., Pashayan, N., Steyerberg, E. W., Widschwendter, M., & Siebert, U. (2021) · The European Journal of Health Economics · doi:10.1007/s10198-021-01338-5 · Cited by 36
Self-citationComprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women
Mars, N., Kerminen, S., Tamlander, M., Pirinen, M., Jakkula, E., Aaltonen, K., Meretoja, T. J., Heinävaara, S. H., Widén, E., Ripatti, S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.00295 · Cited by 36
Of Screening, Stratification, and Scores
Knoppers, B. M., Bernier, A., Moreno, P. G., & Pashayan, N. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080736 · Cited by 35
Self-citationJones, C. K., Scott, S. E., & Waller, J. (2021) · Cancers · doi:10.3390/cancers13225813 · Cited by 35
Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors
Lebrett, M. B., Crosbie, E. J., Smith, M. J., Woodward, E. R., Evans, D. G., & Crosbie, P. A. J. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2020-107399 · Cited by 34
A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound
Rossi, S. H., Klatte, T., Usher‐Smith, J. A., Fife, K. M., Welsh, S. J., Dabestani, S., Bex, A., Nicol, D. L., Nathan, P., Stewart, G. D., et al. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.09.002 · Cited by 33
Wong, J. Z. Y., Chai, J. H., Yeoh, Y. S., Riza, N. K. M., Liu, J. X., Teo, Y.-Y., Wee, H. L., & Hartman, M. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06396-2 · Cited by 31
Barriers and Attitudes toward Breast Cancer Screening among Omani Women
Al-Azri, M. H., Al-Rubaie, K., Al-Ghafri, S., Al‐Hinai, M., & Panchatcharam, S. M. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.5.1339 · Cited by 29
Cost‐effectiveness of risk‐based breast cancer screening: A systematic review
Khan, S. A., Hernández-Villafuerte, K., Muchandifunga Trust Muchadeyi, & Schlander, M. (2021) · International Journal of Cancer · doi:10.1002/ijc.33593 · Cited by 35
Polygenic risk scores: the future of cancer risk prediction, screening, and precision prevention
Wang, Y., Zhu, M., Ma, H., & Shen, H. (2021) · Medical Review · doi:10.1515/mr-2021-0025 · Cited by 32
Pashayan, N., Antoniou, A. C., Lee, A., Wolfson, M. C., Chiquette, J., Eloy, L., Eisen, A. F., Stockley, T. L., Nabi, H., Brooks, J. D., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090916 · Cited by 29
Self-citationLiu, J. X., Ho, P. J., Tan, T. H. L., Yeoh, Y. S., Chew, Y. J., Riza, N. K. M., Khng, A. J., Goh, S.-A., Wang, Y., Oh, H. B., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265965 · Cited by 29
Implementation Challenges for Risk-Stratified Screening in the Era of Precision Medicine
Roberts, M. C. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1940 · Cited by 29
Boulch, M. L., Bekhouche, A., Kermarrec, É., Milon, A., Wahab, C. A., Zilberman, S., Chabbert‐Buffet, N., & Thomassin‐Naggara, I. (2020) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2020.07.004 · Cited by 28
Dennison, R. A., Boscott, R. A., Thomas, R., Griffin, S. J., Harrison, H., John, S. D., Moorthie, S. A., Stephen Morris, A., Rossi, S. H., Stewart, G. D., et al. (2022) · Health Expectations · doi:10.1111/hex.13522 · Cited by 30
Sankatsing, V. D. V., van Ravesteyn, N. T., Heijnsdijk, E. A. M., Broeders, M. J. M., & de Koning, H. J. (2020) · International Journal of Cancer · doi:10.1002/ijc.33126 · Cited by 27
Quinn, E. M., Dunne, E., Flanagan, F. L., Mahon, S., Stokes, M., Barry, M. J., Kell, M. R., & Walsh, S. M. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05806-z · Cited by 27
Jiang, S., Cao, J., ROSNER, B. A., & Colditz, G. A. (2021) · Biometrics · doi:10.1111/biom.13611 · Cited by 27
McGuinness, M., Fassi, E., Wang, C., Hacking, C. C., & Ellis, V. (2020) · Journal of Genetic Counseling · doi:10.1002/jgc4.1347 · Cited by 26
Wolfson, M. C., Gribble, S., Pashayan, N., Easton, D. F., Antoniou, A. C., Lee, A., van Katwyk, S., & Simard, J. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01258-y · Cited by 26
Self-citationRisk prediction models for breast cancer: a systematic review
Zheng, Y., Li, J., Wu, Z. L., Li, H., Cao, M., Li, N., & He, J. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055398 · Cited by 25
Use of Breast Cancer Risk Factors to Identify Risk-Adapted Starting Age of Screening in China
Zheng, Y., Dong, X., Jiang, L., Qin, C., Xu, Y., Wang, F., Cao, W., Xia, C., Yu, Y., Zhao, L., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.41441 · Cited by 24
Epidemiology of Breast Cancer in Sub-Saharan Africa
Adeoye, P. A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109361 · Cited by 24
Esquivel-Sada, D., Lévesque, E., Hagan, J., Knoppers, B. M., & Simard, J. (2019) · Healthcare policy · doi:10.12927/hcpol.2019.26072 · Cited by 24
Usher‐Smith, J. A., Harvey-Kelly, L. L. W., Rossi, S. H., Harrison, H., Griffin, S. J., & Stewart, G. D. (2020) · Health Expectations · doi:10.1111/hex.13175 · Cited by 26
van Ravesteyn, N. T., Schechter, C. B., Hampton, J. M., Alagöz, O., van den Broek, J. J., Kerlikowske, K. M., Mandelblatt, J. S., Miglioretti, D. L., Sprague, B. L., Stout, N. K., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa218 · Cited by 23
Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials
Voronin, D. V., Abalymov, A. A., Svenskaya, Y. I., & Lomova, M. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179149 · Cited by 26
Hawkins, R. L., McWilliams, L., Ulph, F., Evans, D. G., & French, D. (2022) · BMC Cancer · doi:10.1186/s12885-022-10134-0 · Cited by 23
Xia, C., Xu, Y., He, L., He, S., & Chen, W. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101012 · Cited by 23
Jiang, X., McGuinness, J. E., Sin, M., Silverman, T. B., Kukafka, R., & Crew, K. D. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00072 · Cited by 26
Woof, V. G., McWilliams, L., Donnelly, L. S., Howell, A., Evans, D. G., Maxwell, A., & French, D. (2021) · Women s Health · doi:10.1177/17455065211009746 · Cited by 23
Walker, M. J., Blackmore, K. M., Chang, A., Lambert-Côté, L., Turgeon, A., Antoniou, A. C., Bell, K. A., Broeders, M. J. M., Brooks, J. D., Carver, T. J., et al. (2024) · Cancers · doi:10.3390/cancers16112116 · Cited by 22
Self-citationRisk prediction models for esophageal cancer: A systematic review and critical appraisal
Li, H., Sun, D., Cao, M., He, S., Zheng, Y., Yu, X., Wu, Z. L., Lei, L., Peng, J., Li, J., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4226 · Cited by 23
Ayoub, A., Lapointe, J., Nabi, H., & Pashayan, N. (2023) · Genes · doi:10.3390/genes14030732 · Cited by 22
Self-citationEtzioni, R., Gulati, R., Patriotis, C., Rutter, C. M., Zheng, Y., Srivastava, S., & Feng, Z. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad227 · Cited by 23
The ethics of risk-stratified cancer screening
Dennison, R. A., Usher‐Smith, J. A., & John, S. D. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.023 · Cited by 28
Wang, X., Zhou, S., Ye, N., Li, Y., Zhou, P., Gao, C., & Hu, H. Z. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-05044-8 · Cited by 22
Blouin-Bougie, J., Amara, N., & Simard, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060540 · Cited by 21
Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines
Gierach, G. L., Choudhury, P. P., & García‐Closas, M. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3820 · Cited by 21
Petitjean, C., Wilcox, N., Ficorella, L., Dennis, J., Tyrer, J. P., Lush, M. J., Simard, J., Easton, D. F., Antoniou, A. C., & Yang, X. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae335 · Cited by 20
Hussan, H., Zhao, J., Badu-Tawiah, A. K., Stanich, P. P., Tabung, F. K., Gray, D. M., Ma, Q., Kalady, M. F., & Clinton, S. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265209 · Cited by 21
Metadata
- Authors
- Pashayan, N., Morris, S., Gilbert, F. J., & Pharoah, P. D. P.
- Affiliations
- University College London (GB)
- Department of Applied Health Research, University College London, London, England
- University of Cambridge (GB)
- Corresponding author
- Pashayan, Nora
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-11-01
- Volume
- 4
- Issue
- 11
- Pages
- 1504
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC6230256
- OpenAlex
- W2829068939
- Cited by
- 284
- References
- 25
- Citations by year
- 2026: 15 · 2025: 32 · 2024: 35 · 2023: 31 · 2022: 48 · 2021: 49 · 2020: 31 · 2019: 35 · 2018: 8
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- JAMA Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (10119, 16561, C490/A16561, 26884, A16561)
- National Institute for Health and Care Research (NF-SI-0515-10067)
- Engineering and Physical Sciences Research Council (EP/P006485/1)
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Digital Radiography and Breast Imaging
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- breast cancer screening, risk-stratified screening, mammography, overdiagnosis, cost-effectiveness, polygenic risk score, risk thresholds, breast cancer mortality, quality-adjusted life years, net monetary benefit, life table model, women aged 50-69, National Health Service, willingness-to-pay threshold
- MeSH terms
- Aged, Breast Neoplasms, Cost-Benefit Analysis, Female, Humans, Middle Aged, Risk Assessment, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
